6533b81ffe1ef96bd1277122

RESEARCH PRODUCT

Soluble tumor necrosis factor receptor type II in the early diagnosis of fever in neutropenia.

Goetz MEigler ASteinmetz HtG. HeusselGerhard BehreWolfgang HiddemannWeiss M

subject

AdultMalemedicine.medical_specialtyNeutropeniaTime FactorsFevermedicine.medical_treatmentPilot ProjectsNeutropeniaInfectionsGastroenterologySeverity of Illness IndexReceptors Tumor Necrosis FactorSepsisAntigens CDhemic and lymphatic diseasesInternal medicinemedicineHumansReceptors Tumor Necrosis Factor Type IIProspective StudiesAgedChemotherapyHematologyLeukopeniabusiness.industryOsmolar ConcentrationMyeloid leukemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseSolubilityLeukemia MyeloidImmunologyAcute DiseaseTumor necrosis factor alphaFemalemedicine.symptombusinessComplication

description

Sepsis in chemotherapy-associated neutropenia is a major cause of mortality in the treatment of acute myeloid leukemia (AML). Early diagnosis of sepsis is crucial for patient survival. We analyzed the value of prospectively measuring serum concentrations of soluble tumor necrosis factor receptor type II (sTNF-RII) in patients with AML for early diagnosis of sepsis in neutropenia. Therefore, 54 adult patients with AML and neutropenia were followed around the onset of fever. A total of 59 febrile episodes were documented. We could not demonstrate a significant increase in sTNF-RII levels prior to fever. sTNF-RII concentrations were not predictive of the severity of a febrile episode. Based on these data, we cannot recommend the routine screening of sTNF-RII for early detection of septic complications in patients undergoing cytoreductive therapy of AML.

yearjournalcountryeditionlanguage
2002-02-12Annals of hematology
10.1007/s00277-002-0482-3https://pubmed.ncbi.nlm.nih.gov/12185508